The Pharmacy Times® Insights video library presents one-on-one interviews with pharmacy experts, who examine the latest patient counseling tools and innovative solutions for the everyday practice and business.
What can we help you find?
Advancements in Treatment and Management of HER2-Positive Early Breast Cancer: Introduction and the APHINITY Trial
Jacob Kettle, PharmD, BCOP, and Allison Butts, PharmD, BCOP, share insights on some recent trials for early stage breast cancer, specifically the APHINITY trial.
Expert pharmacists provide community physicians with recommendations for optimizing success on treatment for patients with chronic lymphocytic leukemia (CLL).
Experienced pharmacists in the management of chronic lymphocytic leukemia (CLL) discuss the impact of pharmacy-led oral chemotherapy management programs, and how they are implemented.
A discussion on the economic impact that intravenous versus oral therapy has for institutions and patients.
Key opinion leaders discuss which characteristics of oral therapies need to be managed by pharmacists.
A comparison of the safety and efficacy of orally and intravenously administered oncolytics.
A discussion on the management of BTK [Bruton tyrosine kinase] inhibitor toxicities based on longer-term experience.
Key opinion leaders consider their first-line therapy options for treatment-naïve patients with chronic lymphocytic leukemia.
Key opinion leaders discuss trials focusing on patient populations with newly diagnosed chronic lymphocytic leukemia (CLL).
A discussion on the use of BTK (Bruton’s tyrosine kinase) inhibitor monotherapy for newly diagnosed chronic lymphocytic leukemia (CLL) patients, with special consideration of the RESONATE trial regimen.
Experts in the field of chronic lymphocytic management (CLL) consider how MRD (minimum residual disease) testing affects the use of limited duration therapy.
Key opinion leaders consider the decision criteria for selecting a front-line therapy for patients with chronic lymphocytic leukemia (CLL).